```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable scientific reagent extensively utilized in cardiovascular investigations. This monoclonal antibody fragment primarily targets the glycoprotein IIb/IIIa receptor on blood cells, blocking platelet aggregation . Consequently , it's frequently applied as a method to examine the mechanisms underlying thrombosis and to determine the effectiveness of anticoagulant therapies. Supply is typically restricted to research settings.
```
Abciximab Research: Utilizing C7E3 and 143653-53-6 in Studies
Ongoing studies into abciximab, a antiplatelet agent, frequently incorporates the monoclonal antibody C7E3 and the chemical compound identified as 143653-53-6. These reagents are instrumental for analyzing abciximab's mechanism of action, determining its efficacy in experimental conditions, and understanding potential indicators of therapeutic success. Continued study leveraging these precise reagents is expected to provide valuable insights for optimizing therapeutic strategies concerning cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in check here various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Analyzing Scientific Possibilities with the Drug Abciximab 143653-53-6 via C7E3
Recent studies demonstrate that Abciximab (identified as 143653-53-6) holds significant investigative promise, particularly when combined with C7E3. Preliminary findings suggested that this association may enhance patient responses in multiple heart-related contexts. Further examination is directed on understanding the specific mechanism of effect between Abciximab and C7E3, involving analysis of blood clot aggregation and arterial preservation.
- Future investigation work intend to optimize dosing protocols.
- Animal models are were utilized to more assess the propositions.
- Patient trials might be required to thoroughly assess patient effectiveness.
```
Abciximab (C7E3) for Research: Purity and Characteristics (143653-53-6)
Researchers needing C7E3 for laboratory research should rigorously evaluate purity and documented characteristics. This product is typically offered as a freeze-dried powder and thorough analytical documentation including verification by LC-MS, binding affinity assays, and endotoxin testing must be available. Ensure the supplier's certificate of analysis clearly states defined ranges for related substances and fulfills all quality assurance standards .
Pharmaceutical-Grade ReoPro Details & Supply
Acquiring laboratory-grade Abciximab, specifically referencing the antibody C7E3 and identified by the chemical number 143653-53-6, requires detailed consideration of its source . This glycoprotein is frequently utilized in laboratory studies , particularly those related to platelet aggregation and clotting . Existing suppliers offer this reagent in varying amounts , typically ranging from milligram to significant commercial quantities . Please advise reviewing the report of testing to verify quality and appropriateness for your specific use . Additionally , ensure the expiration date before obtaining to maintain maximum performance .
- Standard Purity: >95%
- Preservation Conditions: -20°C or appropriate conditions
- Application : Platelet Adhesion Inhibition Studies